Upgrade to FINVIZ*Elite to get real-time quotes, intraday charts, and advanced charting tools.

Last Close
Oct 24  •  04:00PM ET
34.42
Dollar change
+0.50
Percentage change
1.47
%
Index- P/E- EPS (ttm)-2.12 Insider Own2.98% Shs Outstand112.45M Perf Week2.64%
Market Cap3.89B Forward P/E- EPS next Y-3.70 Insider Trans-1.04% Shs Float109.09M Perf Month37.19%
Enterprise Value3.18B PEG- EPS next Q-0.89 Inst Own67.75% Short Float23.33% Perf Quarter3.67%
Income-237.39M P/S- EPS this Y-168.95% Inst Trans-1.95% Short Ratio3.92 Perf Half Y37.74%
Sales0.00M P/B5.43 EPS next Y-36.07% ROA-28.31% Short Interest25.45M Perf YTD-14.46%
Book/sh6.34 P/C5.44 EPS next 5Y- ROE-29.23% 52W High81.73 -57.89% Perf Year-44.51%
Cash/sh6.32 P/FCF- EPS past 3/5Y-12.29% -23.00% ROIC-33.28% 52W Low18.92 81.92% Perf 3Y869.58%
Dividend Est.- EV/EBITDA- Sales past 3/5Y- - Gross Margin- Volatility6.40% 5.92% Perf 5Y500.70%
Dividend TTM- EV/Sales- EPS Y/Y TTM-126.16% Oper. Margin- ATR (14)2.16 Perf 10Y473.67%
Dividend Ex-Date- Quick Ratio28.34 Sales Y/Y TTM- Profit Margin- RSI (14)60.27 Recom1.12
Dividend Gr. 3/5Y- - Current Ratio28.34 EPS Q/Q-259.40% SMA207.79% Beta0.60 Target Price93.25
Payout- Debt/Eq0.00 Sales Q/Q- SMA5019.40% Rel Volume0.67 Prev Close33.92
Employees36 LT Debt/Eq0.00 EarningsOct 22 AMC SMA20017.55% Avg Volume6.50M Price34.42
IPOApr 29, 2015 Option/ShortYes / Yes EPS/Sales Surpr.-14.15% - Trades Volume4,380,722 Change1.47%
Date Action Analyst Rating Change Price Target Change
Apr-29-25Initiated Cantor Fitzgerald Overweight $104
Apr-08-25Initiated Goldman Neutral $30
Feb-13-25Initiated Scotiabank Sector Outperform $102
Feb-07-25Initiated Citigroup Neutral $38
Dec-02-24Initiated Piper Sandler Overweight
Nov-22-24Initiated B. Riley Securities Buy $109
Nov-04-24Reiterated H.C. Wainwright Buy $90 → $102
Sep-11-24Initiated JP Morgan Overweight $80
Jun-27-24Initiated Morgan Stanley Overweight $105
May-16-24Upgrade Raymond James Outperform → Strong Buy $115 → $116
Oct-23-25 09:28AM
02:54PM
02:36PM
10:39AM
09:55AM
11:01PM Loading…
Oct-22-25 11:01PM
04:05PM
Oct-21-25 07:05AM
Oct-20-25 04:20AM
Oct-17-25 09:54PM
05:45PM
09:30AM
06:22AM
04:15AM
Oct-16-25 11:10AM
09:31AM Loading…
09:31AM
07:45AM
Oct-15-25 04:05PM
Oct-14-25 05:50PM
Oct-13-25 10:15AM
Oct-12-25 09:45AM
Oct-10-25 09:54AM
Oct-09-25 01:37PM
11:00AM
Oct-08-25 05:45PM
12:57AM
Oct-05-25 04:31PM
Oct-02-25 05:45PM
Sep-30-25 10:45AM
09:15AM
04:12AM Loading…
04:12AM
Sep-25-25 05:45PM
09:30AM
09:15AM
04:12AM
Sep-24-25 12:25PM
Sep-23-25 05:50PM
Sep-19-25 10:51AM
04:40AM
Sep-18-25 11:20AM
Sep-17-25 06:22PM
09:53AM
Sep-16-25 02:04PM
12:58PM
08:54AM
Sep-15-25 05:45PM
11:08AM
Sep-11-25 03:43PM
10:02AM
Sep-10-25 10:28AM
Sep-09-25 09:30AM
Sep-08-25 07:33PM
11:58AM
Sep-07-25 11:14AM
Sep-05-25 04:10AM
Sep-04-25 09:00AM
Sep-03-25 01:48PM
Sep-02-25 10:30AM
Sep-01-25 10:54AM
Aug-29-25 05:45PM
04:26AM
Aug-28-25 06:42PM
04:30PM
Aug-27-25 10:52AM
10:00AM
08:11AM
Aug-26-25 04:08PM
11:09AM
09:47AM
06:15AM
Aug-24-25 08:45AM
Aug-23-25 05:00AM
Aug-22-25 11:30AM
10:21AM
08:49AM
Aug-21-25 12:53PM
12:05PM
07:39AM
05:24AM
Aug-20-25 12:59PM
11:56AM
11:41AM
09:30AM
06:57AM
06:06AM
Aug-19-25 07:22PM
04:33PM
03:56PM
02:59PM
02:21PM
01:21PM
12:46PM
11:49AM
11:24AM
11:23AM
11:21AM
11:16AM
10:57AM
10:40AM
10:30AM
Viking Therapeutics, Inc. is a clinical-stage biopharmaceutical company, which engages in the development of therapies for metabolic and endocrine disorders. The company was founded by Brian Lian and Michael A. Dinerman on September 24, 2012 and is headquartered in San Diego, CA.
Insider Trading Relationship Date Transaction Cost #Shares Value ($) #Shares Total SEC Form 4
Lian BrianPresident & CEOJul 03 '25Sale27.8026,889747,6332,388,014Jul 03 03:31 PM
ZANTE GREGChief Financial OfficerJul 03 '25Sale27.764,266118,428168,660Jul 03 03:31 PM
Mancini MariannaChief Operating OfficerJul 03 '25Sale27.774,266118,473377,535Jul 03 03:30 PM
GREG ZANTEOfficerJul 03 '25Proposed Sale27.764,266118,428Jul 03 01:07 PM
MARIANNA MANCINIOfficerJul 03 '25Proposed Sale27.774,266118,473Jul 03 01:05 PM
BRIAN LIANOfficerJul 03 '25Proposed Sale27.8026,889747,633Jul 03 01:01 PM
FOEHR MATTHEW WDirectorApr 11 '25Option Exercise8.0020,786166,288132,036Apr 14 07:26 PM
Rouan Sarah KathrynDirectorMar 31 '25Buy24.151,24029,9431,240Apr 02 06:29 PM
Lian BrianPresident & CEOJan 06 '25Sale42.75194,4908,313,6012,366,570Jan 06 08:16 PM
Mancini MariannaChief Operating OfficerJan 06 '25Sale42.7554,2152,317,599374,134Jan 06 08:15 PM
ZANTE GREGChief Financial OfficerJan 06 '25Sale42.7550,3092,150,595165,259Jan 06 08:14 PM
GREG ZANTEOfficerJan 06 '25Proposed Sale42.7550,3092,150,594Jan 06 05:32 PM
MARIANNA MANCINIOfficerJan 06 '25Proposed Sale42.7554,2152,317,599Jan 06 05:25 PM
BRIAN LIANOfficerJan 06 '25Proposed Sale42.75194,4908,313,611Jan 06 05:16 PM
MACARTNEY LAWSONDirectorNov 08 '24Option Exercise5.802,00011,60049,965Nov 08 06:22 PM
MACARTNEY LAWSONDirectorNov 08 '24Sale68.672,000137,33347,965Nov 08 06:22 PM
LAWSON MACARTNEYDirectorNov 08 '24Proposed Sale68.672,000137,333Nov 08 06:13 PM
ZANTE GREGChief Financial OfficerOct 28 '24Option Exercise7.4994,001704,282281,053Oct 28 09:48 PM
ZANTE GREGChief Financial OfficerOct 28 '24Sale76.61131,68710,089,164149,366Oct 28 09:48 PM
GREG ZANTEOfficerOct 28 '24Proposed Sale78.03131,68710,275,537Oct 28 04:37 PM